Strategic Deal Partner (Biotech Hedge Funds)
Title: Strategic Deal Partner (Biotech Hedge Funds)
Compensation: 20–25% Uncapped Commission + Optional Advisory Equity
Structure: Independent Contractor / Introducer Agreement
Opportunity: Sell Risk Visibility, Not Software.
floatz uses AI to stress-test the science behind biotech programs. Our platform surfaced major toxicity red flags in Rubius ~2 years before its $200M+ collapse.
We’re expanding on the buy-side and seeking a Deal Partner to originate introductions into biotech-focused hedge funds.
This is an access-driven role. Not volume sales.
Who You Are
You’re already connected to PMs or pod leads. Likely backgrounds:
• Expert Networks (GLG/AlphaSights): Ready to monetize real influence.
• Institutional / PB / Research Sales: Fluent in Soft Dollars (28e).
• Cap Intro / HF Connector: Your intros get taken.
You understand:
• binary events • readout risk • drawdowns • scientific failure risk • pass-through expenses
The Role
• Your job: Book a 20-min “Risk Review” with a PM holding a biotech ticker.
• Our job: Run the diligence, present risks, close the engagement.
You focus on origination. Not long cycles.
The Deal
• Commission: 20–25% of the first engagement (uncapped). Most initial engagements fall in the $48.5k–$145k range, translating to $10k–$36k+ per introduction.
• Equity: Optional micro-advisory equity for consistent high-impact originators
• Engagements are short-cycle and fundable via Soft Dollars (28e)
DO NOT APPLY IF...
⛔ You want a base salary
⛔ You’ve never sold to hedge funds
⛔ You struggle with high-level biotech or investment concepts
⛔ You rely on long, multi-touch SaaS sales sequences
This is for people who can create trust-based access to decision-makers.Apply Now
Apply Now
Compensation: 20–25% Uncapped Commission + Optional Advisory Equity
Structure: Independent Contractor / Introducer Agreement
Opportunity: Sell Risk Visibility, Not Software.
floatz uses AI to stress-test the science behind biotech programs. Our platform surfaced major toxicity red flags in Rubius ~2 years before its $200M+ collapse.
We’re expanding on the buy-side and seeking a Deal Partner to originate introductions into biotech-focused hedge funds.
This is an access-driven role. Not volume sales.
Who You Are
You’re already connected to PMs or pod leads. Likely backgrounds:
• Expert Networks (GLG/AlphaSights): Ready to monetize real influence.
• Institutional / PB / Research Sales: Fluent in Soft Dollars (28e).
• Cap Intro / HF Connector: Your intros get taken.
You understand:
• binary events • readout risk • drawdowns • scientific failure risk • pass-through expenses
The Role
• Your job: Book a 20-min “Risk Review” with a PM holding a biotech ticker.
• Our job: Run the diligence, present risks, close the engagement.
You focus on origination. Not long cycles.
The Deal
• Commission: 20–25% of the first engagement (uncapped). Most initial engagements fall in the $48.5k–$145k range, translating to $10k–$36k+ per introduction.
• Equity: Optional micro-advisory equity for consistent high-impact originators
• Engagements are short-cycle and fundable via Soft Dollars (28e)
DO NOT APPLY IF...
⛔ You want a base salary
⛔ You’ve never sold to hedge funds
⛔ You struggle with high-level biotech or investment concepts
⛔ You rely on long, multi-touch SaaS sales sequences
This is for people who can create trust-based access to decision-makers.Apply Now
Apply Now